- Home
- NRIX
as 05-30-2025 4:00pm EST
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 1.1B | IPO Year: | 2020 |
| Target Price: | $30.71 | AVG Volume (30 days): | 739.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.18 - $29.56 | Next Earning Date: | 07-10-2025 |
| Revenue: | $56,417,000 | Revenue Growth: | -30.25% |
| Revenue Growth (this year): | 15.43% | Revenue Growth (next year): | -5.21% |
Stock Insider Trading Activity of Nurix Therapeutics Inc. Common stock (NRIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| van Houte Hans | NRIX | Chief Financial Officer | May 2 '25 | Sell | $11.33 | 6,198 | $70,242.55 | 33,724 | |
| van Houte Hans | NRIX | Chief Financial Officer | Apr 30 '25 | Sell | $11.50 | 2,438 | $28,041.14 | 33,724 | |
| Hansen Gwenn | NRIX | Chief Scientific Officer | Apr 30 '25 | Sell | $11.50 | 3,377 | $38,841.24 | 61,516 | |
| van Houte Hans | NRIX | Chief Financial Officer | Mar 3 '25 | Sell | $14.76 | 5,825 | $84,387.72 | 33,724 |
Latest Nurix Therapeutics Inc. Common stock News
NRIX Breaking Stock News: Dive into NRIX Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire
15 days ago
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
17 days ago
Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
GlobeNewswire
18 days ago
Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma
Insider Monkey
19 days ago
Why Nurix Therapeutics (NRIX) Is Among the Best Low Priced Biotech Stocks to Buy Now
GlobeNewswire
a month ago
Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs
GlobeNewswire
a month ago
Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets
MT Newswires
a month ago
Nurix Says FDA Clears Oral IRAK4 Degrader Application for Inflammatory Diseases; Shares Up Pre-Bell
Compare NRIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NRIX Nurix Therapeutics Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.